Sage Therapeutics is a biotechnology firm that develops and commercializes novel therapies for the treatment of CNS and neurodegenerative disorders.
Business Model:
Revenue: $6.5M
Employees: 201-500
Address: 215 First Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Sage Therapeutics is a biotechnology firm that develops and commercializes novel therapies for the treatment of CNS and neurodegenerative disorders.
Contact Phone:
+16172998380
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
7/21/2014
Ticker Symbol:
SAGE
Amount Raised:
$90M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 10/2013 | Series B | 2 | $20M |
Third Rock Ventures ARCH Venture Partners Third Rock Ventures Third Rock Ventures ARCH Venture Partners Third Rock Ventures |
10/2011 | Series A | 1 | $35M |
Third Rock Ventures Third Rock Ventures Third Rock Ventures Third Rock Ventures |
3/2014 | Series C | 5 | $38M |
Foresite Capital Third Rock Ventures ARCH Venture Partners OrbiMed EcoR1 Capital Foresite Capital Third Rock Ventures ARCH Venture Partners OrbiMed EcoR1 Capital |
11/2017 | Post-IPO Equity | $345M | 9/2016 | Post-IPO Equity | $175M | 1/2016 | Post-IPO Equity | $150M | 2/2019 | Post-IPO Equity | $575M | 2/2018 | Post-IPO Equity | $575M | 4/2015 | Post-IPO Equity | $138M | 1/2014 | Equity | $10M | 7/2014 | IPO | $90M |
|
12/2020 | Post-IPO Equity | $650M | 11/2020 | Post-IPO Equity | 1 | $650M |
Biogen Idec Biogen Idec Biogen Idec Biogen Idec |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|